G
Ghasem Yadegarfar
Researcher at Isfahan University of Medical Sciences
Publications - 96
Citations - 3918
Ghasem Yadegarfar is an academic researcher from Isfahan University of Medical Sciences. The author has contributed to research in topics: Population & Lung cancer screening. The author has an hindex of 25, co-authored 93 publications receiving 3383 citations. Previous affiliations of Ghasem Yadegarfar include University of Manchester & Imperial College London.
Papers
More filters
Journal ArticleDOI
Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
Clive Holmes,Clive Holmes,Delphine Boche,David Wilkinson,David Wilkinson,Ghasem Yadegarfar,Ghasem Yadegarfar,Vivienne Hopkins,Antony James Bayer,Roy W. Jones,Roger Bullock,Seth Love,James Neal,Elina Zotova,James A. R. Nicoll +14 more
TL;DR: Although immunisation with Abeta(42) resulted in clearance of amyloid plaques in patients with Alzheimer's disease, this clearance did not prevent progressive neurodegeneration and there was no evidence of improved survival.
Journal ArticleDOI
UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening
John K. Field,Stephen W. Duffy,David R Baldwin,David K. Whynes,A. Devaraj,Katherine Emma Brain,Timothy Eisen,J. R. Gosney,Beverley A Green,John A Holemans,Terry Kavanagh,Keith M. Kerr,Martin Ledson,Kate Lifford,Fiona E. McRonald,Arjun Nair,Richard D. Page,Mahesh K. B. Parmar,Doris M Rassl,Robert C. Rintoul,Nicholas Screaton,Nicholas J. Wald,David Weller,Paula R Williamson,Ghasem Yadegarfar,David M. Hansell +25 more
TL;DR: The UKLS pilot trial demonstrated that it is possible to detect lung cancer at an early stage and deliver potentially curative treatment in over 80% of cases and health economic analysis suggests that the intervention would be cost effective.
Journal ArticleDOI
The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer.
John K. Field,Stephen W. Duffy,David R Baldwin,Katherine Emma Brain,Anand Devaraj,Tim Eisen,Beverley A Green,John A Holemans,Terry Kavanagh,Keith M. Kerr,Martin Ledson,Kate Lifford,Fiona E. McRonald,Arjun Nair,Richard D. Page,Mahesh K. B. Parmar,Robert C. Rintoul,Nicholas Screaton,Nicholas J. Wald,David Weller,David K. Whynes,Paula R Williamson,Ghasem Yadegarfar,David M. Hansell +23 more
TL;DR: The data from the UKLS provide evidence that adds to existing data to suggest that lung cancer screening in the UK could potentially be implemented in the 60-75 years age group, selected via the Liverpool Lung Project risk model version 2 and using CT volumetry-based management protocols.
Journal ArticleDOI
The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia
TL;DR: This study investigated 60 patients with ET for the presence of the JAK2 mutation and possible phenotypic associations and used the previously published allele-specific polymerase chain reaction (PCR) method on whole blood DNA to detect qualitatively the presence or absence of theJAK2 V617F mutation.
Journal ArticleDOI
Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial
Noor Ali,Kate Lifford,Ben Carter,Fiona E McRonald,Ghasem Yadegarfar,David R Baldwin,David Weller,David M. Hansell,Stephen W. Duffy,John K. Field,Katherine Emma Brain +10 more
TL;DR: A profile of risk factors for non-participation in lung screening has emerged, with underlying reasons largely relating to practical and emotional barriers.